Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository

AIDS

Volumn 28, Issue 16, 2014, Pages 2439-2449

  Kassanjee, Reshma ^a,b   Pilcher, Christopher D ^c   Keating, Sheila M ^d   Facente, Shelley N ^c   McKinney, Elaine ^e   Price, Matthew A ^c,f   Martin, Jeffrey N ^c   Little, Susan ^g   Hecht, Frederick M ^c   Kallas, Esper G ^h   Welte, Alex ^a   Busch, Michael P ^d   Murphy, Gary ^e  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarkers; HIV; Incidence assays; Incidence estimation; Recent infection

Indexed keywords

ARTICLE; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SURVEILLANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONGITUDINAL STUDY; PRACTICE GUIDELINE; COMPARATIVE STUDY; EPIDEMIOLOGY; EVALUATION STUDY; HIV INFECTIONS; LABORATORY TEST; PROCEDURES;

CLINICAL LABORATORY TECHNIQUES; EPIDEMIOLOGIC METHODS; HIV INFECTIONS; HUMANS; INCIDENCE;

EID: 84916197015     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000429     Document Type: Article

References (50)

1. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995;141:166-172.
2. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, Laeyendecker O, et al. Estimating HIV incidence in populations using tests for recent infection: Issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol 2010;2:1-14.
3. Incidence Assay Critical Path Working Group. More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med 2011;8:e1001045.
4. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance. When and how to use assays for recent infection to estimate HIV incidence at a population level. 2011. www.who.int/diagnostics-laboratory/hiv-incidence-may13-final.pdf [Accessed 29 March 2014].
5. Kassanjee R, McWalter TA, Bärnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology 2012;23:721-728.
6. The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). http://www.incidence-estimation.com/page/cephia. [Accessed 29 March 2014].
7. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, et al. Detection of recent HIV-1 infection using a new Limiting-Antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012;7:e33328.
8. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002;18:295-307.
9. Keating SM, Hanson D, Lebedeva M, Laeyendecker O, Ali-Napo NL, Owen SM, et al. Lower-sensitivity and avidity modifications of the Vitros Anti-HIV 1+2 Assay for detection of recent HIV infections and incidence estimation. J Clin Microbiol 2012;50:3968-3976.
10. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K, Rudolph D, et al. Antibody avidity-based assay for identifying recent HIV-1 infections based on Genetic SystemsTM 1/2 plus O EIA. Abstract 937 at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 16-19 February 2010.
11. Bill & Melinda Gates Foundation Letters of Inquiry (LOI): New biomarkers for HIV incidence measurement. https://docs.gatesfoundation.org/Documents/hiv-incidence-rules-and-guidelines.pdf. [Accessed 29 March 2014].
12. American Red Cross. http://www.redcrossblood.org/. [Accessed 29 March 2014].
13. Blood Centers of the Pacific. http://www.bloodcenters.org/. [Accessed 29 March 2014].
14. South African National Blood Service. http://www.sanbs.org.za/. [Accessed 29 March 2014].
15. Fundacao Pro-Sangue Hemocentro de Sao Paulo. http://www.prosangue.sp. gov. br/hemocentros/Default.aspx. [Accessed 29 March 2014].
16. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010;5:e15510.
17. Winkelstein W Jr, Wiley JA, Padian NS, Samuel M, Shiboski S, Ascher MS, et al. The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health 1988;78:1472-1474.
18. Morris SR, Little SJ, Cunningham T, Garfein RS, Richman DD, Smith DM. Evaluation of an HIV nucleic acid testing program with automated internet and voicemail systems to deliver results. Ann Intern Med 2010;152:778-785.
19. Costa PR, Hartogensis W, Diaz RS, Bacchetti P, Hecht R, Santos BR, et al. Subjects infected with clade C-containing HIV exhibit higher CD4+ T cell activation. Poster 289 at the 2014 Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 March 2014.
20. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011;27:5-12.
21. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.
22. Kassanjee R, Murphy G, Busch MP, Pilcher CD, McKinney E, Keating S, et al. The performance of candidate assays to detect recent HIV infection for cross-sectional incidence estimation: an independent, comparative evaluation. Poster 1056/abstract X-168 at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013.
23. Sedia Biosciences Corporation. Sedia BED HIV-1 Incidence EIA: enzyme immunoassay for population estimates of HIV-1 incidence, Cat. No. 1000, 2013. http://www.sediabio.com/LiteratureRetrieve.aspx?ID=108381 [Accessed 27 June 2014].
24. Sedia Biosciences Corporation. Sedia HIV-1 LAg-Avidity EIA: single well avidity enzyme immunoassay for detection of recent HIV-1 infection using liquid serum or plasma, Cat. No. 1002, 2013. http://www.sediabio.com/-literature-122730/LAg-Avidity-EIA-Product-Insert [Accessed 27 June 2014].
25. Sedia Biosciences Corporation. Sedia HIV-1 LAg-Avidity EIA: single well avidity enzyme immunoassay for detection of recent HIV-1 infection, Cat. No. 1002, 2012. http://www.hivincidence.com/uploads/LN-6039-02-Package-Insert-Lag-Avidity-EIA-sm-.pdf [Accessed 29 March 2012].
26. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-1879.
27. Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, et al. Modeling sequence evolution in acute HIV-1 infection. J Theor Biol 2009;261:341-360.
28. Bollinger RC, Brookmeyer RS, Mehendale SM, Paranjape RS, Shepherd ME, Gadkari DA, et al. Risk factors and clinical presentation of acute primary HIV infection in India. J Am Med Assoc 1997;278:2085-2089.
29. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. Diagnosis of primary HIV-1 infection. Ann Intern Med 2001;134:25-29.
30. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002;16:1119-1129.
31. Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FE, Fiscus SA, et al. Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS 2007;21:2237-2242.
32. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-264.
33. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
34. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS 2000;14:2333-2339.
35. Pilcher CD, Eron JJ Jr, Vemazza PL, Battegay M, Harr T, Yerly S, et al. Sexual transmission during the incubation period of primary HIV infection. J Am Med Assoc 2001;286:1713-1714.
36. HIV Modelling Consortium. http://www.hivmodelling.org/. [Accessed 29 March 2014].
37. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol 2013;177:264-272.
38. Efron B, Tibshirani RJ. An introduction to the bootstrap (monographs on statistics and applied probability 57). New York: Chapman & Hall/CRC; 1993.
39. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat 1998;52:119-126.
40. Mehrotra DV, Chan IS, Berger RL. A cautionary note on exact unconditional inference for a difference between two independent binomial proportions. Biometrics 2003;59:441-450.
41. Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, Levy JA, et al. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 2006;22:640-647.
42. Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One 2013;8:e55525.
43. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult AndAdolescentGL.pdf. [Accessed 29 March 2014].
44. South African Department of Health. The South African antiretroviral treatment guidelines, Version 14. http://www.sahiv soc.org/upload/documents/2013%20ART%20Guidelines-Short %20Combined%20FINAL%20draft%20guidelines%2014%20 March%202013.pdf. [Accessed 29 March 2014].
45. Le Vu S, Velter A, Meyer L, Peytavin G, Guinard J, Pillonel J, et al. Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France. PLoS One 2012;7:e39872.
46. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011;52(Suppl 1):S17-22.
47. Curtis KA, Hanson DL, Kennedy MS, Owen SM. Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS One 2013;8:e64201.
48. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis 2013;207:232-239.
49. Kassanjee R, Murphy G, Pilcher C, Busch M, McKinney E, Keating SM, et al. Evaluation panel analysis results. Presentation at satellite session of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013.
50. Kassanjee R, McWalter TA, Welte A. Defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res Hum Retroviruses 2014;30:45-49.